Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 9:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 62 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Injection Drug Use Clear all
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Combined Injectable Treatment for HIV and OUD

NCT05991622
View directory record Official record
Conditions
Human Immunodeficiency Virus, Opioid Use Disorder
Interventions
Combined LAI Treatment: Cabenuva and Sublocade
Drug
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Sep 5, 2026, 9:01 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Project UNITY - HIV Risk Reduction and Vaccine Education Interventions

NCT00150098
View directory record Official record
Conditions
HIV Infections, Hepatitis B
Interventions
Enhanced HIV risk reduction and HIV vaccine education
Behavioral
Lead sponsor
New York Blood Center
Other
Eligibility
18 Years and older · Female only
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
2
States / cities
New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 7, 2014 · Synced Sep 5, 2026, 9:01 AM EDT
Recruiting Not applicable Interventional

Continuum of Care in Hospitalized Patients With Opioid/Stimulant Use Disorder and Infectious Complications From Drug Use

NCT06513156
View directory record Official record
Conditions
Opioid Use Disorder, Injection Related Infections, Stimulant Use Disorder
Interventions
Integrated Infectious Diseases and Substance Use Disorder Clinic (IC)
Behavioral
Lead sponsor
Elana Rosenthal
Other
Eligibility
18 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Sep 5, 2026, 9:01 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Pilot Study to Evaluate Skin Swabbing With Chlorhexidine to Prevent Skin And Soft Tissue Infections Among People Who Inject Drugs

NCT06733506
View directory record Official record
Conditions
Opioid Use Disorder, Injection Drug Use, Skin and Soft Tissue Infections (SSTIs)
Interventions
Chlorhexidine gluconate, Isopropyl Alcohol 70% Topical Application Solution, Skin Prep Before Injecting Recreational/Street Drugs
Drug · Behavioral
Lead sponsor
Gabriel John Culbert
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 2, 2025 · Synced Sep 5, 2026, 9:01 AM EDT
Completed Phase 3 Interventional Results available

Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial Kit

NCT05282004
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration (nAMD)
Interventions
SOK583A1
Drug
Lead sponsor
Sandoz
Industry
Eligibility
50 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
5
States / cities
Poway, California • Marietta, Georgia • Oak Forest, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Sep 5, 2026, 9:01 AM EDT
Recruiting Phase 4 Interventional

Long-acting Cabotegravir Injectable Pre-exposure Prophylaxis for People Who Inject Drugs

NCT07199335
View directory record Official record
Conditions
HIV, Substance Use Disorder (SUD), Injection Drug Use
Interventions
APRETUDE (cabotegravir)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Sep 5, 2026, 9:01 AM EDT
Completed Phase 4 Interventional Results available

Peri-operative Use of a Pain Injection in Pediatric Patients With Cerebral Palsy

NCT04074265
View directory record Official record
Conditions
Cerebral Palsy, Hip Dysplasia, Pain, Postoperative
Interventions
Ropivacaine injection, normal saline
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
Up to 18 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
4
States / cities
Los Angeles, California • Santa Monica, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 9, 2024 · Synced Sep 5, 2026, 9:01 AM EDT
Recruiting Phase 2 Interventional

The Effect and Safety of Anti-inflammatories and Dextrose Prolotherapy Injections in Treating Knee Osteoarthritis

NCT06911359
View directory record Official record
Conditions
Knee Osteoarthritis (OA)
Interventions
Participants are given Ibuprofen 400 mg to take for 7 days on the day they receive a dextrose prolotherapy (DPT) injection. These procedures are repeated every 3-5 weeks for a total of 3 times., Participants are given a placebo to take for 7 days on the day they receive a dextrose prolotherapy (DPT) injection. These procedures are repeated every 3-5 weeks for a total of 3 times.
Drug
Lead sponsor
David Grant U.S. Air Force Medical Center
Federal
Eligibility
45 Years to 75 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Travis AFB, California
Source: ClinicalTrials.gov public record
Updated Nov 23, 2025 · Synced Sep 5, 2026, 9:01 AM EDT
Completed Phase 2 Interventional Results available

Integrated Outpatient Treatment of Opioid Use Disorder and Severe Injection Related Infections

NCT04677114
View directory record Official record
Conditions
Drug Use, Opioid-use Disorder
Interventions
Buprenorphine and Outpatient Parenteral Antibiotic Therapy, Buprenorphine and standard of care antibiotic treatment
Drug
Lead sponsor
Laura Fanucchi
Other
Eligibility
18 Years to 99 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Sep 5, 2026, 9:01 AM EDT
Completed Phase 3 Interventional

A Treatment Protocol for the Use of Trimetrexate With Leucovorin Rescue for AIDS Patients With Pneumocystis Carinii Pneumonia and Serious Intolerance to Approved Therapies

NCT00001016
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Trimetrexate glucuronate, Leucovorin calcium
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2007
U.S. locations
1
States / cities
Morris Plains, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 29, 2008 · Synced Sep 5, 2026, 9:01 AM EDT
Completed Phase 4 Interventional Results available

Control of Pain in Intravitreal Injections Using Topical NSAIDs

NCT04343222
View directory record Official record
Conditions
Intravitreal Injections, IVI
Interventions
Bromfenac, Artificial tears
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 11, 2023 · Synced Sep 5, 2026, 9:01 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Neurophysiology of Weakness and Exercise in Rotator Cuff Tendinopathy

NCT02971072
View directory record Official record
Conditions
Acute Pain, Atrophic, Goals, Impairment, Infiltration, Injury, Muscle Weakness, Pain, Pathology, Shoulder Pain, Syndrome, Tendinopathy
Interventions
Subacromial injection, Physical Therapy
Procedure · Other
Lead sponsor
University of Oregon
Other
Eligibility
21 Years to 45 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2021
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 12, 2022 · Synced Sep 5, 2026, 9:01 AM EDT
Completed Not applicable Interventional

Break the Cycle: Prevention for Reducing Initiation Into Injection Drug Use

NCT03502525
View directory record Official record
Conditions
Substance Abuse, Intravenous, Prevention and Control
Interventions
Break the Cycle Intervention, Bacterial Infection Prevention
Behavioral
Lead sponsor
New York University
Other
Eligibility
18 Years and older
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced Sep 5, 2026, 9:01 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Packaging PrEP to Prevent HIV Among WWID

NCT03304912
View directory record Official record
Conditions
HIV/AIDS
Interventions
PrEP Education and option to accept a PrEP prescription
Behavioral
Lead sponsor
Drexel University
Other
Eligibility
18 Years and older · Female only
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 11, 2023 · Synced Sep 5, 2026, 9:01 AM EDT
Completed No phase listed Observational

Project BEST: Buprenorphine Entry Into Substance Abuse Treatment

NCT02583243
View directory record Official record
Conditions
Opioid-related Disorders, HIV Infections, Hepatitis C, Chronic, Depression
Interventions
MET/CBT based individualized counseling, Buprenorphine
Behavioral · Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 2, 2020 · Synced Sep 5, 2026, 9:01 AM EDT
Completed Phase 3 Interventional Results available

Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Prefilled Syringe

NCT05161806
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration (nAMD)
Interventions
SOK583A1 (40 mg/mL), Prefilled Syringe (PFS)
Drug · Device
Lead sponsor
Sandoz
Industry
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
3
States / cities
Marietta, Georgia • Oak Forest, Illinois • Liverpool, New York
Source: ClinicalTrials.gov public record
Updated Nov 17, 2022 · Synced Sep 5, 2026, 9:01 AM EDT
Not listed Phase 4 Interventional

Evaluating the Use of Prednisone to Decrease Pegylated Interferon Beta-1a Side Effects

NCT03424733
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Plegridy, Prednisone, Tylenol Pill
Drug
Lead sponsor
Holy Name Medical Center, Inc.
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Teaneck, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 14, 2019 · Synced Sep 5, 2026, 9:01 AM EDT
Completed Phase 3 Interventional Results available

Injectable Pharmacotherapy for Opioid Use Disorders (IPOD)

NCT02110264
View directory record Official record
Conditions
Opioid Use Disorders
Interventions
XR-NTX, XR-NTX+PN, ETAU
Drug · Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 100 Years
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jan 21, 2020 · Synced Sep 5, 2026, 9:01 AM EDT
Completed Not applicable Interventional Results available

Testing a Community-Friendly Risk Reduction Intervention for Injection Drug Users

NCT01741350
View directory record Official record
Conditions
HIV, Opioid Dependence
Interventions
Community-friendly Health Recovery Program, Time-and-Attention-Matched Control Condition
Behavioral
Lead sponsor
University of Connecticut
Other
Eligibility
18 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 5, 2026, 9:01 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Integrated HIV Prevention and HCV Care for PWID

NCT03981445
View directory record Official record
Conditions
HIV Prevention, HCV, Opioid Use, Intravenous Drug Usage
Interventions
ARTAS Adapted Patient Navigation, Adherence Counseling
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 64 Years
Enrollment
446 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
2
States / cities
Miami, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 5, 2026, 9:01 AM EDT
Withdrawn Not applicable Interventional

Bupivacaine Injections Into Uterosacral Ligaments During Robotic Assisted Total Hysterectomies

NCT02230735
View directory record Official record
Conditions
Pain
Interventions
Bipivacaine 0.5% with epinephrine, Normal Saline
Drug
Lead sponsor
Souza, Amanda, M.D.
Individual
Eligibility
21 Years to 65 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Farmington Hills, Michigan
Source: ClinicalTrials.gov public record
Updated May 4, 2016 · Synced Sep 5, 2026, 9:01 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Reducing Health Problems Associated With Injection Drug Use

NCT01128920
View directory record Official record
Conditions
Intravenous Drug Abuse, HIV Infections
Interventions
Skin and Needle Hygiene Intervention, No intervention - assessment-only condition
Behavioral · Other
Lead sponsor
University of Northern Colorado
Other
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 3, 2012 · Synced Sep 5, 2026, 9:01 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Correlates and Consequences of Increased Immune Activation in Injection Drug Users

NCT01831284
View directory record Official record
Conditions
Intravenous Drug Usage
Interventions
Sigmoidoscopy with biopsy
Procedure
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 55 Years
Enrollment
201 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 5, 2014 · Synced Sep 5, 2026, 9:01 AM EDT
Completed Phase 4 Interventional

The Kentucky Viral Hepatitis Treatment Study

NCT03949764
View directory record Official record
Conditions
Hepatitis C, Opioid-Related Disorders, Injection Drug Use
Interventions
Sofosbuvir/velpatasvir (Epclusa®)
Drug
Lead sponsor
Jennifer Havens
Other
Eligibility
18 Years and older
Enrollment
374 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Hazard, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Sep 5, 2026, 9:01 AM EDT